Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy +/- Adjuvant Hormonal Therapy in Localized Prostate Cancer
NCT00021450Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2001
- Primary completion
- Apr 2008
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of bicalutamide and goserelin in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Biochemical and Clinical Disease-Free Survival at 5 years. Started Apr 2001; status: completed.
02
Drugs
bicalutamidegoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00021450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021450.